Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 12/2017

25.07.2017 | Original Article

Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery

verfasst von: Gaya Spolverato, MD, Fabio Bagante, MD, Luca Aldrighetti, MD, George Poultsides, MD, Todd W. Bauer, MD, Ryan C. Field, MD, Hugo P. Marques, MD, Matthew Weiss, MD, Shishir K. Maithel, MD, Timothy M. Pawlik, MD, MPH, PhD

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Neuroendocrine tumors typically arise from pancreatic (PNET) vs. gastrointestinal or thoracic origins (non-PNET). The impact of primary tumor site on long-term prognosis following resection of neuroendocrine liver metastasis (NELM) remains poorly defined. The objective of the current study was to define the association of primary tumor location on prognosis of patients undergoing curative intent liver resection for NELM.

Methods

Between 1990 and 2014, 421 patients who underwent resection of NELM were identified from a multi-institutional database. Clinicopathological characteristics, operative details, and outcomes were stratified and analyzed by location of the primary tumor (PNET vs. non-PNET). A propensity score-matched analysis was utilized to assess the impact of primary tumor location on long-term survival.

Results

Among the 421 patients, 197 (46.8%) patients had NELM from a PNET primary while 224 (53.2%) had a non-PNET primary (small bowel, n = 145; rectal, n = 10; bronchial, n = 22; other, n = 47). There were no differences in tumor burden and tumor site, while presence of extrahepatic disease was more common among patients with non-PNET NELM (extrahepatic disease, PNET NELM, n = 11 27.5% vs. non-PNET NELM, n = 29 72.5%; p = 0.010). Patients with PNET NELM were more likely to have non-functional disease compared with patients who had non-PNET NELM (non-functional, PNET NELM, n = 117 54.9% vs. non-PNET NELM, n = 96 45.1%; p = 0.011). On the final pathological specimen of the resected NELM, patients with PNET NELM were more likely to have a moderately differentiated tumor (59.3%), while patients with non-PNET NELM were more likely to have a poorly differentiated tumor (67.8%) (p = 0.005). Patients with PNET NELM had a worse 5-year DFS and 5-year OS compared with patients who had non-PNET NELM (DFS, PNET 36.2% vs. non-PNET 55.2%; p = 0.001 and OS, PNET 79.5% vs. non-PNET 83.4%; p = 0.008). After propensity score matching, both 5-year DFS and 5-year OS of the PNET and non-PNET groups were comparable (DFS, PNET 46.2% vs. non-PNET 55.9%; p = 0.22 and OS, PNET 81.5% vs. non-PNET 84.3%; p = 0.19).

Conclusion

PNET patients more often present with non-functional NELM and moderately differentiated tumors. On propensity-matched analysis, factors such as extrahepatic disease and tumor grade, but not primary tumor location, were associated with prognosis of patients undergoing curative intent liver surgery for NELM.
Literatur
1.
Zurück zum Zitat Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases. Surgical oncology clinics of North America. Jan 2016;25(1):217–225. Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases. Surgical oncology clinics of North America. Jan 2016;25(1):217–225.
2.
Zurück zum Zitat Spolverato G, Bagante F, Wagner D, et al. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. Sep 2015;198(1):155–164. Spolverato G, Bagante F, Wagner D, et al. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. Sep 2015;198(1):155–164.
3.
Zurück zum Zitat Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons. Apr 2000;190(4):432–445. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons. Apr 2000;190(4):432–445.
4.
Zurück zum Zitat Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. Dec 1988;104(6):1011–1017. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. Dec 1988;104(6):1011–1017.
5.
Zurück zum Zitat Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? Journal of the American College of Surgeons. Jul 1998;187(1):88–92; discussion 92–83. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? Journal of the American College of Surgeons. Jul 1998;187(1):88–92; discussion 92–83.
6.
Zurück zum Zitat Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons. Jul 2003;197(1):29–37. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons. Jul 2003;197(1):29–37.
7.
Zurück zum Zitat Knox CD, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. Annals of surgical oncology. Dec 2003;10(10):1171–1175. Knox CD, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. Annals of surgical oncology. Dec 2003;10(10):1171–1175.
8.
Zurück zum Zitat Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. Apr 2006;13(4):572–581. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. Apr 2006;13(4):572–581.
9.
Zurück zum Zitat Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. Feb 15 2003;97(4):934–959. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. Feb 15 2003;97(4):934–959.
10.
Zurück zum Zitat Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. Feb 2011;149(2):209–220. Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. Feb 2011;149(2):209–220.
11.
Zurück zum Zitat Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-related cancer. Dec 2008;15(4):1083–1097. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-related cancer. Dec 2008;15(4):1083–1097.
12.
Zurück zum Zitat Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. The lancet oncology. Jan 2014;15(1):e8–21. Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. The lancet oncology. Jan 2014;15(1):e8–21.
13.
Zurück zum Zitat Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocrine pathology. Fall 2007;18(3):145–149. Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocrine pathology. Fall 2007;18(3):145–149.
14.
Zurück zum Zitat McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. The British journal of surgery. Jul 1994;81(7):1007–1009. McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. The British journal of surgery. Jul 1994;81(7):1007–1009.
15.
Zurück zum Zitat Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Annals of surgical oncology. Dec 2011;18(13):3657–3665. Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Annals of surgical oncology. Dec 2011;18(13):3657–3665.
16.
Zurück zum Zitat Mayo SC, Herman JM, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. Journal of the American College of Surgeons. Jan 2013;216(1):123–134. Mayo SC, Herman JM, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. Journal of the American College of Surgeons. Jan 2013;216(1):123–134.
17.
Zurück zum Zitat Spolverato G, Vitale A, Ejaz A, et al. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery. Aug 2015;158(2):339–348. Spolverato G, Vitale A, Ejaz A, et al. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery. Aug 2015;158(2):339–348.
18.
Zurück zum Zitat Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of surgical oncology. Feb 01 2017. Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of surgical oncology. Feb 01 2017.
19.
Zurück zum Zitat Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Annals of surgical oncology. Dec 2010;17(12):3129–3136. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Annals of surgical oncology. Dec 2010;17(12):3129–3136.
20.
Zurück zum Zitat Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. Aug 2010;39(6):707–712. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. Aug 2010;39(6):707–712.
21.
Zurück zum Zitat Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Digestive surgery. 1999;16(6):459–467. Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Digestive surgery. 1999;16(6):459–467.
22.
Zurück zum Zitat Spolverato G, Pawlik TM. Liver-directed therapies: surgical approaches, alone and in combination with other interventions. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2014:101–110. Spolverato G, Pawlik TM. Liver-directed therapies: surgical approaches, alone and in combination with other interventions. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2014:101–110.
23.
Zurück zum Zitat Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. Feb 28 1996;15(4):361–387. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. Feb 28 1996;15(4):361–387.
24.
Zurück zum Zitat Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surgical oncology. Sep 2012;21(3):e131–141. Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surgical oncology. Sep 2012;21(3):e131–141.
25.
Zurück zum Zitat Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. Jul 01 2008;113(1):126–134. Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. Jul 01 2008;113(1):126–134.
26.
Zurück zum Zitat Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB : the official journal of the International Hepato Pancreato Biliary Association. Aug 2010;12(6):427–433. Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB : the official journal of the International Hepato Pancreato Biliary Association. Aug 2010;12(6):427–433.
27.
Zurück zum Zitat Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. Apr 2003;133(4):375–382. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. Apr 2003;133(4):375–382.
Metadaten
Titel
Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery
verfasst von
Gaya Spolverato, MD
Fabio Bagante, MD
Luca Aldrighetti, MD
George Poultsides, MD
Todd W. Bauer, MD
Ryan C. Field, MD
Hugo P. Marques, MD
Matthew Weiss, MD
Shishir K. Maithel, MD
Timothy M. Pawlik, MD, MPH, PhD
Publikationsdatum
25.07.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 12/2017
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3491-1

Weitere Artikel der Ausgabe 12/2017

Journal of Gastrointestinal Surgery 12/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.